Coherus Net Income from 2010 to 2024
| CHRS Stock | USD 1.21 0.12 11.01% |
Net Loss | First Reported 2012-12-31 | Previous Quarter -12.9 M | Current Value -10.8 M | Quarterly Volatility 50.4 M |
Check Coherus BioSciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Coherus BioSciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2 M, Interest Expense of 42.6 M or Selling General Administrative of 100.1 M, as well as many indicators such as Price To Sales Ratio of 1.16, Dividend Yield of 0.0 or Days Sales Outstanding of 388. Coherus financial statements analysis is a perfect complement when working with Coherus BioSciences Valuation or Volatility modules.
Coherus | Net Income |
Latest Coherus BioSciences' Net Income Growth Pattern
Below is the plot of the Net Income of Coherus BioSciences over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Coherus BioSciences financial statement analysis. It represents the amount of money remaining after all of Coherus BioSciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Coherus BioSciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Coherus BioSciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (237.89 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Coherus Net Income Regression Statistics
| Arithmetic Mean | (127,512,693) | |
| Coefficient Of Variation | (108.95) | |
| Mean Deviation | 116,669,273 | |
| Median | (127,337,000) | |
| Standard Deviation | 138,924,319 | |
| Sample Variance | 19300T | |
| Range | 458.9M | |
| R-Value | (0.44) | |
| Mean Square Error | 16698.5T | |
| R-Squared | 0.20 | |
| Significance | 0.1 | |
| Slope | (13,773,510) | |
| Total Sum of Squares | 270199.5T |
Coherus Net Income History
Other Fundumenentals of Coherus BioSciences
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Coherus BioSciences Net Income component correlations
About Coherus BioSciences Financial Statements
Coherus BioSciences shareholders use historical fundamental indicators, such as Net Income, to determine how well the company is positioned to perform in the future. Although Coherus BioSciences investors may analyze each financial statement separately, they are all interrelated. The changes in Coherus BioSciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Coherus BioSciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -237.9 M | -226 M | |
| Net Loss | -237.9 M | -226 M | |
| Net Loss | -262.6 M | -249.4 M | |
| Net Loss | (2.53) | (2.65) | |
| Net Income Per E B T | 1.00 | 0.81 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.